N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
USRE49850E1 · kind E1 · reissue
0Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 2, 2022 |
| Grant date | Feb 27, 2024 |
| Priority date | — |
| Expiry date | Feb 2, 2042 |
Classification
- Technology area (CPC —)General
Abstract
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.